Abstract
Background: Cytokine-Induced Killer (CIK) cells are a heterogeneous population of ex vivo expanded lymphocytes which exhibit an MHC-unrestricted cytotoxicity against a wide range of tumor histotypes. Moreover, recent reports have also proven that CIK cells express CD16 in a donor-dependent manner, which makes them able to exert Antibody Dependent Cell-Mediated Cytotoxicity (ADCC)[1]. In this study, we aimed at increasing CIK cell antitumor activity using Fc-engineered trastuzumab, bispecific antibodies or recombinant immunoligands, which are able to target both a tumor-associated antigen (Her2) and activating receptors expressed by CIK cells (CD3, NKG2D and NKp30).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
